24/7 Market News Snapshot 23 June, 2025 – Impact BioMedical, Inc. (NYSE:IBO)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (NYSE:IBO) are discussed in this article.
Impact BioMedical, Inc. (IBO) has emerged as a notable player in the stock market, currently priced at $0.766, reflecting a remarkable 111.54% increase from the previous day’s closing figure of $0.362. This surge has been accompanied by a robust pre-market trading volume of 30.22 million shares, showcasing heightened investor interest. Analysts suggest that this bullish momentum may continue, positioning IBO as a prime opportunity for investors seeking growth.

In conjunction with its market activity, Impact BioMedical has entered into a transformative merger agreement with Dr. Ashleys Limited, a significant player in the pharmaceutical industry. Announced on June 21, 2025, this deal entails a reverse merger in which Dr. Ashleys will fully acquire Impact BioMedical, leading to the establishment of a new company that will operate under the name “Dr. Ashleys Limited” on the NYSE American.

This strategic merger is poised to leverage Impact BioMedical’s extensive portfolio, comprising over 90 patents, while integrating Dr. Ashleys’ established research and development capabilities. The collaboration aims to accelerate the advancement and commercialization of innovative treatments across various critical health issues, including cancer and infectious diseases.

Dr. Kanans Visvanats, Director of Dr. Ashleys Limited, emphasized that this merger marks a pivotal moment in enhancing global health by uniting resources to expedite the delivery of transformative pharmaceutical solutions. Meanwhile, Frank D. Heuszel, CEO of Impact BioMedical, noted that the partnership would enable the integration of significant financial resources and global reach, facilitating impactful advancements in healthcare.

With both companies’ boards approving the merger, the transaction now awaits regulatory approvals and fulfillment of customary closing conditions, setting the stage for a promising future in biopharmaceutical innovation.

Related news for (IBO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.